Compare JAKK & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAKK | SABS |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.9M | 201.4M |
| IPO Year | N/A | N/A |
| Metric | JAKK | SABS |
|---|---|---|
| Price | $17.59 | $3.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $36.67 | $9.80 |
| AVG Volume (30 Days) | 109.4K | ★ 397.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.54 | N/A |
| P/E Ratio | $33.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.87 | $1.00 |
| 52 Week High | $35.79 | $6.60 |
| Indicator | JAKK | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 40.87 |
| Support Level | $17.23 | $3.94 |
| Resistance Level | $18.49 | $4.30 |
| Average True Range (ATR) | 0.63 | 0.31 |
| MACD | -0.17 | -0.06 |
| Stochastic Oscillator | 22.73 | 28.33 |
Jakks Pacific Inc is a multi-product line, multi-brand toy company that designs, produces, markets, sells and distributes toys and related kid-targeted consumer products, inclusive of kids indoor and outdoor furniture, costumes and various product lines in the sporting goods and home furnishings space. Its products offering include Traditional toys and electronics such as Action figures, Toy vehicles, Dolls and accessories, Ride-on toys, Toys for pets, and others. The company's products have been divided into two segments: (i) Toys/Consumer Products and (ii) Costumes.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.